All In Biotech

NDA 208219 · Bausch and Lomb INC

Lotemax Sm

Loteprednol Etabonate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Feb 22, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Feb 22, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

944

290 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

LOTEMAX ® SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. LOTEMAX ® SM is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. ( 1 )

Mechanism: Loteprednol etabonate is a corticosteroid. Corticosteroids have been shown to inhibit the inflammatory response to a variety of inciting agents. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 22, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • LOTEMAX SM · LOTEPREDNOL ETABONATE 0.38% · GEL, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain163
  • eye irritation116
  • vision blurred74
  • product use in unapproved indication72
  • off label use67
  • drug ineffective60
  • headache56
  • ocular hyperaemia53
  • photophobia47
  • product dose omission issue45
  • fatigue40
  • inappropriate schedule of product administration40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20053
20081
20092
20104
20112
20123
20135
20143
20158
20165
20176
201811
201950
202073
202188
2022132
2023133
2024157
2025135
2026120

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lotemax Sm (Loteprednol Etabonate)

2024 spending

$14.6M

Beneficiaries

31,185

54,978 claims

Per beneficiary

$469

$49.87 per unit

View as table
YearSpending
2020$13,445,315
2021$19,814,283
2022$22,346,702
2023$20,534,043
2024$14,640,745

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.